Related Experiment Video

Updated: Mar 20, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer

Tommaso De Marchi1, John A Foekens1, Arzu Umar1

  • 1Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.

Drug Discovery Today
|May 29, 2016
PubMed

Insights

Estrogen receptor-positive breast cancer is common, and while endocrine therapies work, resistance is a problem. This review explores new ways to find biomarkers for resistance and improve treatment.

Area of Science:

  • Oncology
  • Endocrinology
  • Biomarker Discovery

Background:

  • Estrogen receptor (ER)-positive breast cancer accounts for the majority of breast malignancies.
  • Endocrine therapies are standard treatments but face challenges with acquired resistance.
  • Understanding resistance mechanisms is crucial for improving patient outcomes.

Purpose of the Study:

  • To review the current state of biomarker discovery for endocrine resistance in ER-positive breast cancer.
  • To highlight the latest technological advancements in identifying resistance markers.
  • To discuss the clinical applicability of these biomarkers.

Main Methods:

  • Review of recent high-throughput studies and technological developments.
  • Analysis of strategies for biomarker discovery.
  • Evaluation of clinical implementation challenges.

Main Results:

  • Various high-throughput approaches are being utilized to identify resistance mechanisms and biomarkers.
  • Technological advancements are accelerating biomarker discovery.
  • Significant opportunities exist, but clinical implementation faces restrictions.

Conclusions:

  • Biomarker discovery for endocrine resistance is rapidly evolving.
  • Translating these discoveries into clinical practice requires addressing current limitations.
  • Further research is needed to optimize biomarker use in managing ER-positive breast cancer.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K
Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

7.2K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K